DE69920679D1 - Neue behandlungen für nervenkrankheiten - Google Patents

Neue behandlungen für nervenkrankheiten

Info

Publication number
DE69920679D1
DE69920679D1 DE69920679T DE69920679T DE69920679D1 DE 69920679 D1 DE69920679 D1 DE 69920679D1 DE 69920679 T DE69920679 T DE 69920679T DE 69920679 T DE69920679 T DE 69920679T DE 69920679 D1 DE69920679 D1 DE 69920679D1
Authority
DE
Germany
Prior art keywords
new treatments
nervous diseases
reboxetine
noradrenaline reuptake
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920679T
Other languages
English (en)
Other versions
DE69920679T2 (de
Inventor
Adriana Dubini
Michael Mccall
Paul Taylor
Voigtlander F Von
Ho Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co
Original Assignee
Pharmacia Italia SpA
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA, Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia Italia SpA
Publication of DE69920679D1 publication Critical patent/DE69920679D1/de
Application granted granted Critical
Publication of DE69920679T2 publication Critical patent/DE69920679T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69920679T 1998-04-13 1999-04-02 Neue behandlungen für nervenkrankheiten Expired - Fee Related DE69920679T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8163298P 1998-04-13 1998-04-13
US81632P 1998-04-13
IT98MI000870 IT1305322B1 (it) 1998-04-23 1998-04-23 Uso di reboxetina per il trattamento di disturbi nervosi
ITMI980870 1998-04-23
US8503398P 1998-05-11 1998-05-11
US85033P 1998-05-11
PCT/US1999/004288 WO1999052518A2 (en) 1998-04-13 1999-04-02 New treatments for nervous disorders

Publications (2)

Publication Number Publication Date
DE69920679D1 true DE69920679D1 (de) 2004-11-04
DE69920679T2 DE69920679T2 (de) 2006-03-02

Family

ID=11379879

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920679T Expired - Fee Related DE69920679T2 (de) 1998-04-13 1999-04-02 Neue behandlungen für nervenkrankheiten

Country Status (25)

Country Link
US (1) US6391876B1 (de)
EP (1) EP1071418B1 (de)
JP (1) JP2002511408A (de)
KR (1) KR100555279B1 (de)
CN (1) CN1197569C (de)
AT (1) ATE277617T1 (de)
AU (1) AU755612B2 (de)
BR (1) BR9909476A (de)
CA (1) CA2320722A1 (de)
DE (1) DE69920679T2 (de)
DK (1) DK1071418T3 (de)
EA (1) EA003546B1 (de)
ES (1) ES2228035T3 (de)
HU (1) HUP0101748A3 (de)
IL (1) IL138887A0 (de)
IT (1) IT1305322B1 (de)
NO (1) NO20005131D0 (de)
NZ (1) NZ507693A (de)
PL (1) PL194039B1 (de)
PT (1) PT1071418E (de)
SI (1) SI1071418T1 (de)
SK (1) SK14482000A3 (de)
TR (1) TR200002970T2 (de)
WO (1) WO1999052518A2 (de)
ZA (1) ZA200004480B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
ATE305788T1 (de) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SI1196172T1 (sl) * 1999-07-01 2006-06-30 Pharmacia & Upjohn Co Llc (S,S)-reboksetin za zdravljenje kronicne bolecine
EP1395253A2 (de) * 2000-11-15 2004-03-10 Eli Lilly And Company Behandlung von angstzuständen
PL375211A1 (en) * 2002-06-17 2005-11-28 Pharmacia Italia S.P.A. Pharmaceutical salts of reboxetine
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals

Also Published As

Publication number Publication date
EA003546B1 (ru) 2003-06-26
CN1197569C (zh) 2005-04-20
ZA200004480B (en) 2002-04-24
AU755612B2 (en) 2002-12-19
US6391876B1 (en) 2002-05-21
PL346294A1 (en) 2002-01-28
EP1071418B1 (de) 2004-09-29
NO20005131L (no) 2000-10-12
DK1071418T3 (da) 2005-01-03
SK14482000A3 (sk) 2001-08-06
SI1071418T1 (en) 2005-04-30
HUP0101748A3 (en) 2001-12-28
KR100555279B1 (ko) 2006-03-03
BR9909476A (pt) 2000-12-19
WO1999052518A3 (en) 1999-12-02
CA2320722A1 (en) 1999-10-21
PL194039B1 (pl) 2007-04-30
ITMI980870A1 (it) 1999-10-23
HUP0101748A2 (hu) 2001-11-28
IT1305322B1 (it) 2001-05-04
EP1071418A2 (de) 2001-01-31
TR200002970T2 (tr) 2001-01-22
JP2002511408A (ja) 2002-04-16
ES2228035T3 (es) 2005-04-01
IL138887A0 (en) 2001-11-25
NO20005131D0 (no) 2000-10-12
NZ507693A (en) 2003-08-29
EA200001058A1 (ru) 2001-04-23
PT1071418E (pt) 2004-12-31
ATE277617T1 (de) 2004-10-15
AU3635199A (en) 1999-11-01
DE69920679T2 (de) 2006-03-02
CN1293569A (zh) 2001-05-02
KR20010042641A (ko) 2001-05-25
WO1999052518A2 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
ATE277617T1 (de) Neue behandlungen für nervenkrankheiten
MY134110A (en) Combinations of reboxetine and neuroleptic agents
FI972922A0 (fi) Tarkkaamattomuuden ja yliaktiivisuuden hoito
ATE329588T1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen
ATE318135T1 (de) Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
PT946166E (pt) Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas
DE50313386D1 (de) Mittelwalze eines Kalanders mit einer Tilgeranordnung
WO2002077198A8 (en) Methods of modulating angiogenesis
SI1923073T1 (sl) Kombinirano zdravilo ki vsebuje pde-5 inhibitor
AR021155A1 (es) Tratamiento de desordenes neuroticos
ES2118569T3 (es) Procedimiento para la regeneracion de un catalizador.
EA200400793A1 (ru) Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции
PT1075264E (pt) Novas combinacoes farmacologicas de reboxetina e pindolol
WO2002040006A3 (en) Treatment of anxiety disorders
CO4950552A1 (es) Nueva composicion lectivos de la reabsorcion de seotonina y un bloqueador b
PT1054671E (pt) Nova utilizacao da ropivacaina para o controlo da dor
ECSP034647A (es) Uso de factor vii actividad de coagulacion para tratar sangrados graves inducidos por terapia
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
ATE406880T1 (de) Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
DE69935881D1 (de) Bis-Indolylmaleimide zur therapeutischen Behandlung von Nieren-Funktionsstörungen
ATE235899T1 (de) Neue therapeutische anwendung von verbindungen mit beta-3-agonistischer aktivität
DK1558610T3 (da) Substituerede aminoquinuclidinforbindelser og deres anvendelse som delta-opioidreceptorligander
FI972378A0 (fi) Menetelmä orgaanisia ja epäorgaanisia yhdisteitä sisältävien jätevesien katalyyttiseksi käsittelemiseksi
ZA991638B (en) Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders and autism.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee